假基因DUXAP8在肝癌中的表达及其临床意义

王纯; 叶明亮; 陈志航; 罗杰; 洪莹晖; 赵秋; 常莹

doi:10.3969/j.issn.1001-5256.2020.03.022

假基因DUXAP8在肝癌中的表达及其临床意义

DOI: 10.3969/j.issn.1001-5256.2020.03.022

1. 武汉大学中南医院消化内科
2. 广西医科大学第一附属医院结直肠肛门外科

基金项目:

国家自然科学基金项目(81670554)；湖北省自然科学基金项目(2017CFA068)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1002
- HTML全文浏览量: 18
- PDF下载量: 210
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-07
- 出版日期: 2020-03-20

Expression and clinical significance of pseudogene DUXAP8 in liver cancer

Department of Gastroenterology,Zhongnan Hospital of Wuhan University

Research funding:

摘要

摘要: 目的探讨DUXAP8在肝癌中的表达和临床意义,并探讨可能的作用机制。方法收集TCGA数据库中截至2019年6月的肝癌表达数据及临床资料,筛选出同时满足在癌组织与癌旁组织差异表达且影响患者预后的lncRNA。分析DUXAP8表达水平与肝癌患者临床病理特征以及预后的相关性。利用GO和KEGG通路富集方法分析与DUXAP8相关的基因生物功能及其可能参与的生物过程。利用STRING数据库和Cytoscape进行蛋白质相互作用分析并筛选关键基因,然后对关键基因的表达量及其预后情况进行分析并进行文献检索分析。肝癌组织和癌旁组织DUXAP8表达比较采用Wilcoxon秩和检验和Wilcoxon符号秩和检验。不同临床病理特征的患者DUXAP8表达水平比较采用Wilcoxon秩和检验。利用Kaplan-Meier法绘制生存曲线并采用log-rank检验进行组间比较;采用Cox回归分析预后影响因素。Pearson相关法分析DUXAP8的相关基因。结果非配对样品及配对样品肝癌组织和癌旁组织中DUXAP8的表达水平存在显著差异（P值均<0. 001）,肝癌组织中DUXAP8表达明显升高。在不同年龄、T分...
- 癌,肝细胞 /
- 假基因 /
- DUXAP8
Abstract: Objective To investigate the expression,clinical significance,and potential mechanism of action of DUXAP8 in hepatocellular carcinoma. Methods The expression data of liver cancer and related clinical data published up to June 2019 were collected from TCGA database to screen out the differentially expressed long non-coding RNAs( lncRNAs) between liver cancer tissue and adjacent tissue which affected the prognosis of patients. The association of the expression level of DUXAP8 with clinicopathological features and prognosis was analyzed. Gene ontology( GO) and KEGG pathway enrichment analysis was used to investigate the biological functions and biological processes of DUXAP8-related genes. The STRING database and Cytoscape were used to analyze protein-protein interactions and screen out key genes,and then the expression levels of key genes and prognosis were analyzed and a literature search analysis was performed. The Wilcoxon signed-rank test and the Wilcoxon rank-sum test were used to compare the expression of DUXAP8 between liver cancer tissue and adjacent tissue,and the Wilcoxon rank-sum test was used to compare the expression of DUXAP8 between the patients with different clinicopathological features. The Kaplan-Meier method was used to plot survival curves and the log-rank test was used for survival comparison between groups; a Cox regression analysis was used to identify the influencing factors for prognosis. A Pearson correlation analysis was used to analyze DUXAP8-related genes. Results As for the matched and unmatched samples,there was a significant difference in the expression of DUXAP8 between liver cancer tissue and adjacent tissue( P < 0. 001),and the expression of DUXAP8 in liver cancer tissue was significantly higher than that in adjacent tissue. There was a significant difference in the expression of DUXAP8 between the patients with different ages or T stages( P < 0. 05),and the patients with an age of ≥60 years or a T stage of T3 or T4 tended to have higher expression of DUXAP8. The univariate analysis showed that clinical stage,T stage,and expression of DUXAP8 were associated with patients' overall survival( all P <0. 001),and the multivariate Cox regression analysis showed that an advanced clinical stage( hazard ratio [HR]= 1. 648,95% confidence interval [CI]: 1. 330-2. 709,P < 0. 001) and high expression of DUXAP8( HR = 1. 849,95% CI: 1. 262-2. 713,P < 0. 01) were independent risk factors for poor prognosis. The genes involved in the maintenance of tumor cell proliferation and cell cycle were enriched in the samples with high expression of DUXAP8. TOP2 A,KIF2 C,TTK,PLK1,CDCA8,CDC20,NCAPG,BUB1 B,BUB1,and CCNA2 were the Hub genes of DUXAP8-related genes and were mainly involved in the processes such as cell mitosis and cell cycle,and they were the factors for poor prognosis of patients with liver cancer( all P < 0. 05). Conclusion The high expression of DUXAP8 is a risk factor for poor prognosis in patients with liver cancer and DUXAP8 may promote the development and progression of liver cancer by affecting the processes of cell proliferation and cell cycle.
- carcinoma,hepatocellular /
- pseudogene /
- DUXAP8

HTML全文

参考文献(23)

[1] FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):e359-e386.

[2] MCGUIRE S. World Cancer Report 2014. Geneva,Switzerland:World Health Organization,International Agency for Research on Cancer,WHO Press,2015[J]. Adv Nutr,2016,7(2):418-419.

[3] PROUDFOOT N. Pseudogenes[J]. Nature,1980,286(5776):840-841.

[4] LUCO R F,MISTELI T. More than a splicing code:Integrating the role of RNA,chromatin and non-coding RNA in alternative splicing regulation[J]. Curr Opin Genet Dev,2011,21(4):366-372.

[5] MARTIANOV I,RAMADASS A,SERRA B A,et al. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript[J]. Nature,2007,445(7128):666-670.

[6] XIA T,LIAO Q,JIANG X,et al. Long noncoding RNA associated-competing endogenous RNAs in gastric cancer[J]. Sci Rep,2014,4:6088.

[7] SAEINASAB M,BAHRAMI AR,GONZALEZ J,et al. SNHG15is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation,invasion and drug resistance in colorectal cancer by interacting with AIF[J]. J Exp Clin Cancer Res,2019,38(1):172.

[8] XU Z,YANG F,WEI D,et al. Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma[J]. Oncogene,2017,36(14):1965-1977.

[9] LI Y,LI J,LUO M,et al. Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma[J]. Cancer Lett,2018,430:57-66.

[10] JIANG B,HAILONG S,YUAN J,et al. Identification of oncogenic long noncoding RNA SNHG12 and DUXAP8 in human bladder cancer through a comprehensive profiling analysis[J]. Biomed Pharmacother,2018,108:500-507.

[11] SUN M,NIE F Q,ZANG C,et al. The pseudogene DUXAP8promotes non-small-cell lung cancer cell proliferation and invasion by epigenetically silencing EGR1 and RHOB[J]. Mol Ther,2017,25(3):739-751.

[12] LIAN Y,YANG J,LIAN Y,et al. DUXAP8,a pseudogene derived lncRNA,promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2[J]. Cancer Commun(Lond),2018,38(1):64.

[13] HUANG T,WANG X,YANG X,et al. Long non-coding RNA DUXAP8 enhances renal cell carcinoma progression via downregulating miR-126[J]. Med Sci Monit,2018,24:7340-7347.

[14] LI Y,ZHUANG W,HUANG M,et al. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma[J]. Biochem Biophys Res Commun,2019,514(4):1051-1057.

[15] LIAO HT,HUANG JW,LAN T,et al. Identification of the aberrantly expressed lncRNA in hepatocellular carcinoma:A bioinformatics analysis based on RNA-sequencing[J]. Sci Rep,2018,8(1):5395.

[16] OUYANG H,ZHANG L,XIE Z,et al. Long noncoding RNA MAFG-AS1 promotes proliferation,migration and invasion of hepatocellular carcinoma cells through downregulation of miR-6852[J]. Exp Ther Med,2019,18(4):2547-2553.

[17] WANG L,GUO ZY,ZHANG R,et al. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma[J]. Carcinogenesis,2013,34(8):1773-1781.

[18] JOHNSSON P,ACKLEY A,VIDARSDOTTIR L,et al. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells[J]. Nat Struct Mol Biol,2013,20(4):440-446.

[19] BOOTH HA,HOLLAND PW. Annotation,nomenclature and evolution of four novel homeobox genes expressed in the human germ line[J]. Gene,2007,387(1-2):7-14.

[20] BREL V,ANNEREAU JP,VISPE S,et al. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anticancer drug F14512 targeting topoisomerase II[J]. Biochem Pharmacol,2011,82(12):1843-1852.

[21] NITISS J L. Targeting DNA topoisomerase II in cancer chemotherapy[J]. Nat Rev Cancer,2009,9(5):338-350.

[22] LIU LM,XIONG DD,LIN P,et al. DNA topoisomerase 1 and2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride[J]. Int J Oncol,2018,53(5):1897-1912.

[23] PANVICHIAN R,TANTIWETRUEANGDET A,ANGKATHUNYAKUL N,et al. TOP2A amplification and overexpression in hepatocellular carcinoma tissues[J]. Biomed Res Int,2015,2015:381602.

施引文献

资源附件(0)

访问统计